# Preoperative Chemotherapy, Pembrolizumab and Low or High Dose RADiation in an Expansion Cohort of Node(+), Triple Negative Breast Cancer

Source: https://onco.cc/trials/nct07276880/  
OnCo record `nct07276880` (Trial). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

A phase 2 trial in triple-negative breast cancer, run by UNC Lineberger Comprehensive Cancer Center, now recruiting.

## Summary

Preoperative Chemotherapy, Pembrolizumab and Low or High Dose RADiation in an Expansion Cohort of Node(+), Triple Negative Breast Cancer is a phase 2, randomised interventional study registered as NCT07276880 by UNC Lineberger Comprehensive Cancer Center, with a registry enrolment figure of 32 participants, started 2026-03-17 and due to reach its primary completion in 2027-11. Interventions recorded: Neoadjuvant Pembrolizumab; low dose neoadjuvant boost; High dose neoadjuvant boost. Conditions listed: Breast Cancer; Triple Negative Breast Cancer (TNBC); HER2-Negative Breast Carcinoma; Node-positive Breast Cancer. Sites: United States. No results are recorded here; the registry entry is the source.

## Fields

- Kind: Trial
- Status: recruiting
- Last checked: 2026-09-24
- Also known as: P-RAD(+)TN-DCT
- Tags: ctgov-ingest; tnbc-deep-dive
- Registry id: NCT07276880
- Phase: 2
- Setting: Preoperative Chemotherapy, Pembrolizumab and Low or High Dose RADiation in an Expansion Cohort of Node(+), Triple Negative Breast Cancer
- Sponsor: UNC Lineberger Comprehensive Cancer Center
- Enrolled: 32

## Sources

- ClinicalTrials.gov NCT07276880: https://clinicaltrials.gov/study/NCT07276880

## Connected records

- cancers: [Early triple-negative breast cancer](https://onco.cc/cancers/tnbc-early/)
- terms: [Triple-negative breast cancer trials open today (registry snapshot and UK sites)](https://onco.cc/terms/tnbc-trials-open-today/)

---
JSON: https://onco.cc/api/v1/entities/nct07276880.json